Improving management of renal tumors using artificial intelligence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the management of renal tumors through the use of multimodal artificial intelligence (AI). It will evaluate the accuracy of AI predictions regarding tumor characteristics such as benign or malignant status, subtypes, grading, and staging based on preoperative CT images. Additionally, the study seeks to assist clinicians in determining the most appropriate surgical approach and to integrate CT images with pathology slides for better prognostic information. Participants will undergo active surveillance and have their postoperative survival data recorded for five years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with renal tumor which can be treated by surgery;
* Complete CECT within 30 days before surgery;
* Patients who fully understand this study and sign the informed consent;

Exclusion Criteria:

* Patients with any item missing from the baseline clinical and pathological information;
* Patients who has already metastasized by the time the tumor is discovered;
* Previous treatment in any form, including surgery, targeted therapy and immunotherapy;

Where it's running

• The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Shao Pengfei, Professor
• Email: spf032@hotmail.com
• Phone: +8613851925825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Off-clamp, sutureless robot-assisted partial nephrectomy vs conventional robot-assisted partial nephrectomy

  This trial tests whether removing a small kidney tumor without clamping the blood supply and without stitching the kidney bed preserves kidney function better than the standard robot-assisted surgery.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07888608

• Contrast-enhanced ultrasound and super-resolution imaging to predict kidney function after nephrectomy

  This project will test whether special ultrasound scans—contrast-enhanced ultrasound and super-resolution imaging—can help predict kidney function and the risk and recovery of acute kidney injury in adults having partial or radical nephrectomy for kidney cancer.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT07294859

• AI-driven real-time 3D kidney model to assist partial nephrectomy

  This trial will test whether an AI-powered real-time 3D kidney model can help surgeons perform laparoscopic or robotic partial nephrectomy for adults with small, localized kidney tumors.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT07020169

• Nivolumab plus cabozantinib for older adults with kidney cancer

  This trial tests the combination of nivolumab and cabozantinib in people aged 70 and older with metastatic clear-cell kidney cancer to see how it is used and tolerated in routine care.

  Recruiting Phase 4 Gustave Roussy, Cancer Campus, Grand Paris · Angers and 6 other locations · NCT06934057

• Treating the main kidney tumor in metastatic kidney cancer during immunotherapy

  This trial will see if adding surgery or radiotherapy to the main kidney tumor helps people with metastatic clear‑cell kidney cancer who are already benefiting from anti‑PD1–based therapy live longer.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06903312

• Using AI to predict kidney function after partial kidney removal

  This study is testing if a new AI tool can accurately predict how well your kidneys will work after you have part of one removed due to cancer.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT06751498

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.